Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist

    MISSISSAUGA, ON, Feb. 24 /CNW/ - Nuvo Research Inc. (TSX: NRI), a
Canadian drug development company focused on the research and development of
drug products delivered to and through the skin using its topical and
transdermal drug delivery technologies, today announced that Nuvo's
INSIGHT(TM) platform, developed by its San Diego based research and
development subsidiary, fqubed, Inc., has been selected as one of four
finalists in the Science and Medical category for the prestigious 2009 Edison
Best New Product Awards(TM). The awards honour excellence in new product
development, marketing, and innovation. Finalists in other categories include
the Apple iPhone and Procter & Gamble's Olay Regenerist(R).
    Skin-based or transdermal delivery is a sought-after mode of
therapeutically administering molecules through the skin and into the body.
Skin is a challenging barrier and measuring the effectiveness of multiple
formulations' ability to pass through the skin is a prerequisite to developing
optimized transdermal and topical treatments. INSIGHT is Nuvo's high
throughput experimentation ("HTE") skin permeability screening platform that
is 100-times faster than the traditional method of measuring the
permeabilizing effect of a drug formulation. INSIGHT's key technological
innovation is that it measures skin permeabilization indirectly, via changes
in the skin's electrical impedance caused by application of a formulation.
This dramatically speeds the measurement process and has allowed fqubed to
discover extremely effective molecular penetration enhancer systems.
    "This nomination is indicative of the cutting-edge research and
development that we are doing at Nuvo Research," said John M. Newsam, fqubed's
President and Managing Director. "INSIGHT is being used to accelerate the
development of Nuvo's own topical and transdermal drug pipeline and also to
open doors with potential partners seeking to co-develop therapeutic products
using our HTE skin permeability screening platform."
    The Edison Best New Product Awards, sponsored this year by Google, The
Nielsen Company and Steelcase, focus on new products and services that excel
in marketplace innovation, marketplace success, technological innovation,
market structure innovation, and societal impact. These criteria align with
Edison's own innovation best practices, called the Five Competencies of
Innovation(TM). Gold, Silver and Bronze winners will be announced at an Awards
Gala on April 1, 2009 at the Computer History Museum in Mountain View,
California. For more information about The Edison Awards, visit
www.edisonawards.com.

    About Nuvo Research Inc.

    Nuvo is focused on the research and development of drug products
delivered to and through the skin using its topical and transdermal drug
delivery technologies. Nuvo's lead product is Pennsaid, a topical
non-steroidal anti-inflammatory drug, used for the treatment of
osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to
create a portfolio of topical and transdermal products targeting a variety of
indications.
    Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company
headquartered in Mississauga, Ontario, with manufacturing facilities in
Varennes, Québec and Wanzleben, Germany and a research and development center
in San Diego, California. For more information, please visit
www.nuvoresearch.com.

    These forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. The Company
considers the assumptions on which these forward-looking statements are based
to be reasonable at the time they were prepared, but caution that these
assumptions regarding future events, many of which are beyond the control of
the Company, may ultimately prove to be incorrect. Factors and risks, which
could cause actual results to differ materially from current expectations, are
discussed in the annual report, as well as in the Company's Annual Information
Form for the year ended December 31, 2007. The Company disclaims any intention
or obligation to update or revise any forward-looking statements whether a
result of new information or future events, except as required by law. For
additional information on risks and uncertainties relating to these
forward-looking statements, investors should consult the Company's ongoing
quarterly filings, annual report and Annual Information Form and other filings
found on SEDAR at www.sedar.com.

For further information: about Nuvo, please contact: Media and Investor
Relations, Adam Peeler, The Equicom Group Inc., Tel: (416) 815-0700 x225,
email: apeeler@equicomgroup.com